Indeed, 2 subgroups of anti-CENPA can explain variable clinical manifestations in an ACA-positive subset.87 Subgrouping among patients with SSc positive for anti-RPC155 antibodies (RNAP III large subunit, 155 kDa) revealed that anti-RPA194 was associated with a lower cancer risk and less severe GI disease, while anti-RNAP I/II/III was associated with SRC.75 Therefore, different autoantibody combinations have utility as tools for organ involvement and cancer risk stratification in SSc. This evidence concerns the gene CENPA and systemic sclerosis.